secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0000886163-24-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q4 net income $18.2M ($1.03 diluted); reaffirms 2024 guidance
--------------------------------------------------------------------

- Q4 total revenue $28.1M (down from $50.4M in Q4 2022, which included $23.5M COVID Captisol sales); core adjusted EPS $1.05 vs $0.75.
- Full-year 2023 royalties $83.9M (+16% YoY); core adjusted net income $71.7M ($4.06/diluted) vs $41.9M ($2.44).
- 2024 guidance reaffirmed: total revenue $130-142M, adjusted EPS $4.25-4.75.
- FDA approved ZELSUVMI (berdazimer gel) for molluscum contagiosum; Merck's V116 vaccine granted priority review (PDUFA June 17, 2024).
- Travere's FILSPARI sNDA for IgAN planned Q1 2024; FSGS data insufficient; Aldeyra received CRL for reproxalap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/0000886163-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/lgnd-20240227.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer